托特罗定和奥昔布宁治疗原发性儿童膀胱过度活动症的疗效和安全性比较

Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder

摘要:

目的：比较托特罗定和奥昔布宁在小儿原发性膀胱过度活动症（OAB）的疗效和安全性。方法：共204例确诊为OAB的患儿随机分为安慰剂组68例、托特罗定组68例和奥昔布宁组68例，疗程2周后评估疗效及安全性。结果：安慰剂组总有效率为25%，托特罗定组总有效率达89%，奥昔布宁组有效率达92%，托特罗定组和奥昔布宁组疗效明显高于安慰剂组（P<0.05），托特罗定组和奥昔布宁组疗效相似。托特罗定组不良反应发生率为28%，而奥昔布宁组不良反应发生率为57%,托特罗定组不良反应发生率明显低于奥昔布宁组（P<0.05）。结论：在小儿OAB的药物治疗中，托特罗定和奥昔布宁疗效相似，但托特罗定具有更好的安全性。

Abstract:

OBJECTIVE: To compare the efficacy and safety of tolterodine and oxybutynin in the treatment of idiopathic overactive bladder in children. METHODS: A total of 204 children with idiopathic overactive bladder were randomly divided into three groups (n=68 each): placebo, tolterodine-treated and oxybutynin-treated. The efficacy and safety were evaluated two weeks after treatment. RESULTS: The effective rate was 25% in the placebo group, 89% in the tolterodine-treated group, and 92% in the oxybutynin-treated group. The effective rate in the two treatment groups was significantly higher than that in the placebo group (P<0.05). There was a similar efficacy between the two treatment groups. The incidence of adverse events in the tolterodine-treated group (28%) was significantly lower than that in the oxybutnin-treated group (57%) (P<0.05). CONCLUSIONS: Tolterodine has a similar efficacy to oxybutynin in the treatment of idiopathic overactive bladder in children, with better safety in pharmacotherapy.